Post by account_disabled on Feb 28, 2024 4:38:43 GMT
RedHill Biopharma releases preliminary data from Phase 2 study indicating efficacy and safety of Opaganib in COVID-19 patients. Preliminary data from a US phase 2 trial of opaganib involving 40 hospitalized patients. Oral opaganib has been shown to be safe. There were no significant safety differences between the opaganib-treated group and the control group. The opaganib group showed a continued improvement trend in terms of treatment efficacy in both primary and secondary outcomes. Oxygenation can be reduced at the end of treatment day 14, which has been associated with improved clinical trial results according to World Health Organization (WHO) scales. The opaganib group showed more improvements than the placebo group, including breathing room air within .
14 days (52.6% vs. 22.2%); Supplemental oxygen was Portugal Phone Number reduced by 50% within 14 days (89.5% vs. 66.7%); Proportion of patients discharged within 14 days (73.7% vs. 55.6%) and mean oxygen reduction (AUC) within 14 days (68.0% vs. 46.7%) Key data from a global phase 2/3 trial of 270 hospitalized COVID-19 patients. This is expected in the first quarter of 2021, and the results of preliminary data analysis by the DSMB are expected to be known in the coming weeks. Opaganib targets human cell components that are involved in viral replication. It has the potential to reduce the chance of drug resistance from virus mutation. RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company. Announced today that Preliminary data from a phase 2 study in the United States demonstrate the efficacy and safety of oral opaganib (Yeliva®, ABC294640)[1] in hospitalized patients with lung conditions.
Inflammation from COVID-19 The phase 2 study in the US is a randomized study. Double-blind and placebo-controlled. To prove the efficacy and safety of opaganib (NCT04414618) in 40 patients requiring oxygen support. The study aims to assess the safety and find out the drug's effects. Patients in the study were randomized 1:1 to receive opaganib or placebo in addition to standard treatment (SoC) and were followed up for up to 42 days after starting treatment. – Main data from studies show that opaganib is safe. There were no significant safety differences between the opaganib-treated group and the placebo-treated group. Overall, patients in the opaganib group experienced fewer serious adverse events (SAEs). than the placebo group While few people were put on a ventilator or died - this was about the same between the two groups - the opaganib group showed a trend that continued to improve.
14 days (52.6% vs. 22.2%); Supplemental oxygen was Portugal Phone Number reduced by 50% within 14 days (89.5% vs. 66.7%); Proportion of patients discharged within 14 days (73.7% vs. 55.6%) and mean oxygen reduction (AUC) within 14 days (68.0% vs. 46.7%) Key data from a global phase 2/3 trial of 270 hospitalized COVID-19 patients. This is expected in the first quarter of 2021, and the results of preliminary data analysis by the DSMB are expected to be known in the coming weeks. Opaganib targets human cell components that are involved in viral replication. It has the potential to reduce the chance of drug resistance from virus mutation. RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company. Announced today that Preliminary data from a phase 2 study in the United States demonstrate the efficacy and safety of oral opaganib (Yeliva®, ABC294640)[1] in hospitalized patients with lung conditions.
Inflammation from COVID-19 The phase 2 study in the US is a randomized study. Double-blind and placebo-controlled. To prove the efficacy and safety of opaganib (NCT04414618) in 40 patients requiring oxygen support. The study aims to assess the safety and find out the drug's effects. Patients in the study were randomized 1:1 to receive opaganib or placebo in addition to standard treatment (SoC) and were followed up for up to 42 days after starting treatment. – Main data from studies show that opaganib is safe. There were no significant safety differences between the opaganib-treated group and the placebo-treated group. Overall, patients in the opaganib group experienced fewer serious adverse events (SAEs). than the placebo group While few people were put on a ventilator or died - this was about the same between the two groups - the opaganib group showed a trend that continued to improve.